Skip to main content

Table 2 Multivariate analysis for pCR

From: Immune microenvironment, homologous recombination deficiency, and therapeutic response to neoadjuvant chemotherapy in triple-negative breast cancer: Japan Breast Cancer Research Group (JBCRG)22 TR

 

Intratumoral CD4

Stromal CD4

HR

95% CI

P value

HR

95% CI

P value

Age

0.93

0.853–1.011

0.072

0.9

0.821–0.996

0.024

Dose

1.073

1.005–1.147

0.0073

1.059

0.994–1.13

0.032

HRD

0.92

0.848–1.005

0.053

0.92

0.841–1.007

0.058

Treatment

  

0.035

  

0.026

A1

Reference

Reference

A2

0.48

0.35

B1

2.61×10−11

1.92×10−11

B2

0.016

0.013

Intratumoral CD4

1.008

0.997–1.019

0.009

   

Stromal CD4

   

1.0023

1.0002–1.0044

0.0057

  1. A1 group taking paclitaxel + carboplatin, A2 group taking eribulin + carboplatin, B1 eribulin + cyclophosphamide, B2 eribulin + capecitabine, CI confidence interval, HR hazard ratio, Dose dose of paclitaxel in group A1, eribulin in groups A2, B1 and B2, HRD homologous recombination deficiency, pCR pathological complete response
  2. Statistically significant P values are shown in italics